Clinical Trial Results:
A Phase III, Open-label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular
Carcinoma
Summary
|
|
EudraCT number |
2017-003691-31 |
Trial protocol |
PL DE GB CZ ES IT |
Global end of trial date |
17 Nov 2022
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
21 Oct 2023
|
First version publication date |
01 Sep 2021
|
Other versions |
v1 |
Version creation reason |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
YO40245
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03434379 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
F. Hoffmann-La Roche AG
|
||
Sponsor organisation address |
Grenzacherstrasse 124, Basel, Switzerland, CH-4070
|
||
Public contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
|
||
Scientific contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Nov 2022
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
17 Nov 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the study is to evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who had received no prior systemic treatment.
|
||
Protection of trial subjects |
All study participants were required to read and sign an Informed Consent Form.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Mar 2018
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
3 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Australia: 9
|
||
Country: Number of subjects enrolled |
Canada: 5
|
||
Country: Number of subjects enrolled |
China: 135
|
||
Country: Number of subjects enrolled |
Czechia: 5
|
||
Country: Number of subjects enrolled |
Germany: 16
|
||
Country: Number of subjects enrolled |
Spain: 11
|
||
Country: Number of subjects enrolled |
France: 42
|
||
Country: Number of subjects enrolled |
United Kingdom: 13
|
||
Country: Number of subjects enrolled |
Hong Kong: 18
|
||
Country: Number of subjects enrolled |
Italy: 17
|
||
Country: Number of subjects enrolled |
Japan: 61
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 47
|
||
Country: Number of subjects enrolled |
Poland: 23
|
||
Country: Number of subjects enrolled |
Russian Federation: 24
|
||
Country: Number of subjects enrolled |
Singapore: 17
|
||
Country: Number of subjects enrolled |
Taiwan: 41
|
||
Country: Number of subjects enrolled |
United States: 74
|
||
Worldwide total number of subjects |
558
|
||
EEA total number of subjects |
114
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
300
|
||
From 65 to 84 years |
250
|
||
85 years and over |
8
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
Participants were enrolled at 117 sites in 17 countries: Australia, Canada, China, Czech Republic, Germany, Spain, France, United Kingdom, Hong Kong, Italy, Japan, Republic of Korea, Poland, Russian Federation, Singapore, Taiwan, United States. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
The study included 558 participants with 501 in the Global population. An additional 57 participants enrolled during the China Extension. The total China population included 137 Chinese participants from the Global population plus 57 participants from the China extension. The Global population and the China population were analysed separately. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Period
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
No
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Sorafenib - Global | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Sorafenib
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Sorafenib was administered by mouth, 400 mg twice per day, on Days 1-21 of each 21-day cycle.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Atezolizumab + Bevacizumab - Global | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Bevacizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Bevacizumab was administered by IV, 15 mg/kg on Day 1 of each 21- day cycle.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Atezolizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Atezolizumab was administered by IV, 1200 mg on Day 1 of each 21-day cycle.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Sorafenib - China | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Sorafenib
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Sorafenib was administered by mouth, 400 mg twice per day, on Days 1-21 of each 21-day cycle.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Atezolizumab + Bevacizumab - China | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Bevacizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Bevacizumab was administered by IV, 15 mg/kg on Day 1 of each 21- day cycle.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Atezolizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Atezolizumab was administered by IV, 1200 mg on Day 1 of each 21-day cycle.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall Period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Sorafenib - Global
|
||
Reporting group description |
Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||
Reporting group title |
Atezolizumab + Bevacizumab - Global
|
||
Reporting group description |
Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||
Reporting group title |
Sorafenib - China
|
||
Reporting group description |
Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||
Reporting group title |
Atezolizumab + Bevacizumab - China
|
||
Reporting group description |
Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. |
|
|||||||||||||||||||
End point title |
Overall Survival (OS) in the Global Population [1] | ||||||||||||||||||
End point description |
OS was defined as the time from randomization to death from any cause. Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment. 9999/99999 = not estimable due to the limited number
of events observed
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)
|
||||||||||||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
OS at CCOD 30 months - Global | ||||||||||||||||||
Statistical analysis description |
Stratified by
geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline alpha-fetoprotein
(AFP: <400 vs. >/= 400 ng/mL).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.0009 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.66
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.52 | ||||||||||||||||||
upper limit |
0.85 | ||||||||||||||||||
Statistical analysis title |
OS at CCOD 18 months- Global | ||||||||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline alpha-fetoprotein (AFP: <400 vs. >/= 400 ng/mL).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.0006 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.58
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.42 | ||||||||||||||||||
upper limit |
0.79 |
|
|||||||||||||
End point title |
Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population [2] | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
PFS-IRF RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.59
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.47 | ||||||||||||
upper limit |
0.76 |
|
|||||||||||||||||||
End point title |
Overall Survival (OS) in the China Population [3] | ||||||||||||||||||
End point description |
OS was defined as the time from randomization to death from any cause. China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment. 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)
|
||||||||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
OS at CCOD 30 months - China | ||||||||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.0019 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.53
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.35 | ||||||||||||||||||
upper limit |
0.8 | ||||||||||||||||||
Statistical analysis title |
OS at CCOD 18 months - China | ||||||||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.0026 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.44
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.25 | ||||||||||||||||||
upper limit |
0.76 |
|
|||||||||||||
End point title |
PFS-IRF per RECIST v1.1 in the China Population [4] | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
PFS-IRF RECIST v1.1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0117 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.6
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.4 | ||||||||||||
upper limit |
0.9 |
|
|||||||||||||
End point title |
Objective Response Rate by IRF-Assessment (ORR-IRF) per RECIST v1.1 in the Global Population [5] | ||||||||||||
End point description |
ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
ORR-IRF RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
485
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
2.9
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.68 | ||||||||||||
upper limit |
5.01 |
|
|||||||||||||
End point title |
Objective Response Rate by IRF-Assessment (ORR-IRF) per Hepatocellular Carcinoma (HCC) modified RECIST (mRECIST) in the Global Population [6] | ||||||||||||
End point description |
ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
ORR-IRF HCC mRECIST - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
483
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
3.39
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
2.02 | ||||||||||||
upper limit |
5.71 |
|
|||||||||||||
End point title |
ORR by Investigator-Assessment (ORR-INV) per RECIST v1.1 in the Global Population [7] | ||||||||||||
End point description |
ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
ORR-INV RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
500
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
6.15
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
2.99 | ||||||||||||
upper limit |
12.66 |
|
|||||||||||||
End point title |
Duration of Response by IRF Assessment (DOR-IRF) per HCC mRECIST in the Global Population [8] | ||||||||||||
End point description |
DOR: the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least 30% decrease in the sum of diameters of all target lesions compared to baseline, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition, the sum of diameters must also demonstrate an absolute increase of >/= 5 mm. The analysis population included Global participants with a confirmed response (CR or PR). 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
DOR-IRF HCC mRECIST - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
129
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0048 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.3
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.12 | ||||||||||||
upper limit |
0.73 |
|
|||||||||||||
End point title |
Duration of Response by IRF-Assessment (DOR-IRF) per RECIST v1.1 in the Global Population [9] | ||||||||||||
End point description |
DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 mm. The analysis population included Global participants with a confirmed response (CR or PR). 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
DOR-IRF RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
108
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0051 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.23
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.08 | ||||||||||||
upper limit |
0.7 |
|
|||||||||||||
End point title |
Duration of Response by Investigator Assessment (DOR-INV) per RECIST v1.1 in the Global Population [10] | ||||||||||||
End point description |
DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 mm. The analysis population included Global participants with a confirmed response (CR or PR). 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
DOR-INV RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
95
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.4187 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.59
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.16 | ||||||||||||
upper limit |
2.15 |
|
|||||||||||||
End point title |
PFS-IRF per HCC mRECIST in the Global Population [11] | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
PFS-IRF HCC mRECIST - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.59
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.46 | ||||||||||||
upper limit |
0.74 |
|
|||||||||||||
End point title |
PFS by Investigator Assessment (PFS-INV) per RECIST v1.1 in the Global Population [12] | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
PFS-INV RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.45
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.36 | ||||||||||||
upper limit |
0.57 |
|
|||||||||||||
End point title |
Time to Progression (TTP) by IRF Assessment (TTP-IRF) per RECIST v1.1 in the Global Population [13] | ||||||||||||
End point description |
Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
TTP-IRF RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0105 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.7
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.53 | ||||||||||||
upper limit |
0.92 |
|
|||||||||||||
End point title |
TTP-IRF per HCC mRECIST in the Global Population [14] | ||||||||||||
End point description |
Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
TTP-IRF HCC mRECIST - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0063 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.69
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.52 | ||||||||||||
upper limit |
0.9 |
|
|||||||||||||
End point title |
TTP by Investigator Assessment (TTP-INV) per RECIST v1.1 in the Global Population [15] | ||||||||||||
End point description |
Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
TTP-INV RECIST v1.1 - Global | ||||||||||||
Statistical analysis description |
Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.44
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.35 | ||||||||||||
upper limit |
0.57 |
|
|||||||||||||||||||
End point title |
Overall Survival by Baseline AFP in the Global Population [16] | ||||||||||||||||||
End point description |
OS was defined as the time from randomization to death from any cause. Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment. Subpopulations with baseline AFP <400 ng/mL and AFP>/= 400 ng/mL were analyzed. 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From randomization to death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||||||||
Notes [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
OS AFP >/=400 ng/mL - Global | ||||||||||||||||||
Statistical analysis description |
AFP >/= 400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.0879 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.67
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.42 | ||||||||||||||||||
upper limit |
1.06 | ||||||||||||||||||
Statistical analysis title |
OS AFP <400 ng/mL - Global | ||||||||||||||||||
Statistical analysis description |
AFP <400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.0019 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.5
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.32 | ||||||||||||||||||
upper limit |
0.78 |
|
|||||||||||||||||||
End point title |
PFS-IRF per RECIST v1.1 by Baseline AFP in the Global Population [17] | ||||||||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment. Subpopulations with baseline AFP <400 ng/mL and AFP>/= 400 ng/mL were analyzed.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||||||||
Notes [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
PFS-IRF RECIST v1,1 AFP>/=400 ng/mL - Global | ||||||||||||||||||
Statistical analysis description |
AFP >/=400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.2159 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.78
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.53 | ||||||||||||||||||
upper limit |
1.15 | ||||||||||||||||||
Statistical analysis title |
PFS-IRF RECIST v1,1 AFP<400 ng/mL - Global | ||||||||||||||||||
Statistical analysis description |
AFP<400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.5
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.37 | ||||||||||||||||||
upper limit |
0.68 |
|
|||||||||||||||||||
End point title |
PFS-INV per RECIST v1.1 by Baseline AFP in the Global Population [18] | ||||||||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment. Subpopulations with baseline AFP <400 ng/mL and AFP>/= 400 ng/mL were analyzed.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||||||||
Notes [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
PFS-INV RECIST v1.1 AFP>/=400 ng/mL - Global | ||||||||||||||||||
Statistical analysis description |
AFP >/=400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.0002 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.51
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.35 | ||||||||||||||||||
upper limit |
0.73 | ||||||||||||||||||
Statistical analysis title |
PFS-INV RECIST v1.1 AFP<400 ng/mL - Global | ||||||||||||||||||
Statistical analysis description |
AFP <400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).
|
||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||
Number of subjects included in analysis |
501
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||
Method |
Logrank | ||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||
Point estimate |
0.42
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.31 | ||||||||||||||||||
upper limit |
0.57 |
|
||||||||||||||||||||||
End point title |
Time to Deterioration (TTD) in the Global Population [19] | |||||||||||||||||||||
End point description |
TTD was defined as the time from randomization to the first deterioration (decrease from baseline of >/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks. Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment. 99999 = not estimable due to the limited number of events observed
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
|||||||||||||||||||||
Notes [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
||||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
TTD Physical Functioning - Global | |||||||||||||||||||||
Statistical analysis description |
Physical Functioning: Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
|||||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
|||||||||||||||||||||
Number of subjects included in analysis |
501
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
< 0.0001 | |||||||||||||||||||||
Method |
Logrank | |||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | |||||||||||||||||||||
Point estimate |
0.53
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.39 | |||||||||||||||||||||
upper limit |
0.73 | |||||||||||||||||||||
Statistical analysis title |
TTD Role Functioning - Global | |||||||||||||||||||||
Statistical analysis description |
Role Functioning: Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
|||||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
|||||||||||||||||||||
Number of subjects included in analysis |
501
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
= 0.0019 | |||||||||||||||||||||
Method |
Logrank | |||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | |||||||||||||||||||||
Point estimate |
0.62
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.46 | |||||||||||||||||||||
upper limit |
0.84 | |||||||||||||||||||||
Statistical analysis title |
TTD GHS/QoL - Global | |||||||||||||||||||||
Statistical analysis description |
GHS/QoL: Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
|||||||||||||||||||||
Comparison groups |
Sorafenib - Global v Atezolizumab + Bevacizumab - Global
|
|||||||||||||||||||||
Number of subjects included in analysis |
501
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
= 0.0028 | |||||||||||||||||||||
Method |
Logrank | |||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | |||||||||||||||||||||
Point estimate |
0.63
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.46 | |||||||||||||||||||||
upper limit |
0.85 |
|
||||||||||
End point title |
Percentage of Participants With Adverse Events (AEs) in the Global Population [20] | |||||||||
End point description |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Global safety population included all randomized Global participants who received any amount of study drug with participants grouped according to the treatment the participant actually received.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Up to end of study (up to approximately 40 months)
|
|||||||||
Notes [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Trough Serum Concentration (Cmin) of Atezolizumab in the Global Population [21] | ||||||||||||||||||||
End point description |
The pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16
|
||||||||||||||||||||
Notes [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population [22] | ||||||||
End point description |
The pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Post-dose on Day 1 of Cycle 1
|
||||||||
Notes [22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the Global Population [23] | ||||||||||||
End point description |
The Global ADA-evaluable population was defined as all participants in the Global population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 30 months)
|
||||||||||||
Notes [23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the Global population. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Objective Response Rate by IRF-Assessment (ORR-IRF) per RECIST v1.1 in the China Population [24] | ||||||||||||
End point description |
ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
ORR-IRF RECIST v1,1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
190
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0036 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
4.6
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.53 | ||||||||||||
upper limit |
13.86 |
|
|||||||||||||
End point title |
Objective Response Rate by IRF-Assessment (ORR-IRF) per Hepatocellular Carcinoma (HCC) modified RECIST (mRECIST) in the China Population [25] | ||||||||||||
End point description |
ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
ORR-IRF HCC mRECIST - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
187
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0013 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
4.71
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.72 | ||||||||||||
upper limit |
12.87 |
|
|||||||||||||
End point title |
ORR by Investigator-Assessment (ORR-INV) per RECIST v1.1 in the China Population [26] | ||||||||||||
End point description |
ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
ORR-INV RECIST v1.1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0052 | ||||||||||||
Method |
Cochran-Mantel-Haenszel | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
5.05
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.47 | ||||||||||||
upper limit |
17.39 |
|
|||||||||||||
End point title |
Duration of Response by IRF-Assessment (DOR-IRF) per RECIST v1.1 in the China Population [27] | ||||||||||||
End point description |
DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 mm. The analysis population included China participants with a confirmed response (CR or PR). 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
DOR-IRF RECIST v1.1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
36
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.4581 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.37
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.02 | ||||||||||||
upper limit |
5.85 |
|
|||||||||||||
End point title |
Duration of Response by IRF Assessment (DOR-IRF) per HCC mRECIST in the China Population [28] | ||||||||||||
End point description |
DOR: the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least 30% decrease in the sum of diameters of all target lesions compared to baseline, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition, the sum of diameters must also demonstrate an absolute increase of >/= 5 mm. The analysis population included Global participants with a confirmed response (CR or PR). 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
DOR-IRF HCC mRECIST - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
43
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.01 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.08
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.01 | ||||||||||||
upper limit |
0.91 |
|
|||||||||||||
End point title |
Duration of Response by Investigator Assessment (DOR-INV) per RECIST v1.1 in the China Population [29] | ||||||||||||
End point description |
DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 mm. The analysis population included China participants with a confirmed response (CR or PR). 9999/99999 = not estimable due to the limited number of events observed
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
DOR-INV RECIST v1.1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.3477 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.33
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.03 | ||||||||||||
upper limit |
3.69 |
|
|||||||||||||
End point title |
PFS-IRF per HCC mRECIST in the China Population [30] | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
PFS-IRF HCC mRECIST - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0103 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.59
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.4 | ||||||||||||
upper limit |
0.89 |
|
|||||||||||||
End point title |
PFS by Investigator Assessment (PFS-INV) per RECIST v1.1 in the China Population [31] | ||||||||||||
End point description |
PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
PFS-INV RECIST v1.1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0002 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.49
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.33 | ||||||||||||
upper limit |
0.71 |
|
|||||||||||||
End point title |
Time to Progression (TTP) by IRF Assessment (TTP-IRF) per RECIST v1.1 in the China Population [32] | ||||||||||||
End point description |
Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
TTP-IRF RECIST v1.1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0927 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.68
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.43 | ||||||||||||
upper limit |
1.07 |
|
|||||||||||||
End point title |
TTP-IRF per HCC mRECIST in the China Population [33] | ||||||||||||
End point description |
Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
TTP-IRF HCC mRECIST - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0861 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.67
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.43 | ||||||||||||
upper limit |
1.06 |
|
|||||||||||||
End point title |
TTP by Investigator Assessment (TTP-INV) per RECIST v1.1 in the China Population [34] | ||||||||||||
End point description |
Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of >/= 5 millimeters (mm). China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
||||||||||||
Notes [34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
TTP-INV RECIST v1.1 - China | ||||||||||||
Statistical analysis description |
Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
||||||||||||
Number of subjects included in analysis |
194
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0004 | ||||||||||||
Method |
Logrank | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.49
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.33 | ||||||||||||
upper limit |
0.74 |
|
||||||||||||||||||||||
End point title |
Time to Deterioration (TTD) in the China Population [35] | |||||||||||||||||||||
End point description |
TTD was defined as the time from randomization to the first deterioration (decrease from baseline of >/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks. China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment. 9999/99999 = not estimable due to the limited number of events observed
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)
|
|||||||||||||||||||||
Notes [35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
||||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
TTD Physical Functioning - China | |||||||||||||||||||||
Statistical analysis description |
Physical Functioning: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
|||||||||||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
|||||||||||||||||||||
Number of subjects included in analysis |
194
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
= 0.0035 | |||||||||||||||||||||
Method |
Logrank | |||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | |||||||||||||||||||||
Point estimate |
0.45
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.26 | |||||||||||||||||||||
upper limit |
0.78 | |||||||||||||||||||||
Statistical analysis title |
TTD GHS/QoL - China | |||||||||||||||||||||
Statistical analysis description |
GHS/QoL: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
|||||||||||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
|||||||||||||||||||||
Number of subjects included in analysis |
194
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
= 0.0135 | |||||||||||||||||||||
Method |
Logrank | |||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | |||||||||||||||||||||
Point estimate |
0.53
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.32 | |||||||||||||||||||||
upper limit |
0.88 | |||||||||||||||||||||
Statistical analysis title |
TTD Role Functioning - China | |||||||||||||||||||||
Statistical analysis description |
Role Functioning: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. >/= 400 ng/mL).
|
|||||||||||||||||||||
Comparison groups |
Sorafenib - China v Atezolizumab + Bevacizumab - China
|
|||||||||||||||||||||
Number of subjects included in analysis |
194
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
||||||||||||||||||||||
P-value |
= 0.2214 | |||||||||||||||||||||
Method |
Logrank | |||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | |||||||||||||||||||||
Point estimate |
0.71
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.42 | |||||||||||||||||||||
upper limit |
1.23 |
|
||||||||||
End point title |
Percentage of Participants With Adverse Events (AEs) in the China Population [36] | |||||||||
End point description |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. China safety population included all randomized China participants who received any amount of study drug with participants grouped according to the treatment the participant actually received.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Up to end of study (up to approximately 40 months)
|
|||||||||
Notes [36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Trough Serum Concentration (Cmin) of Atezolizumab in the China Population [37] | ||||||||||||||||||||
End point description |
The pharmacokinetic (PK)-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16
|
||||||||||||||||||||
Notes [37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population [38] | ||||||||
End point description |
The pharmacokinetic (PK)-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Post-dose on Day 1 of Cycle 1
|
||||||||
Notes [38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population [39] | ||||||||||||
End point description |
The China ADA-evaluable population was defined as all participants in the China population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 18 months)
|
||||||||||||
Notes [39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This Endpoint is only reporting the data for the China population. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to end of study (up to approximately 56 months)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety population: all randomized participants who received any amount of study drug with participants grouped according to the treatment the participant actually received. Reported here are the analyses of the Global and China safety populations.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Atezolizumab + Bevacizumab - Global
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Atezolizumab + Bevacizumab - China
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Sorafenib - China
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Sorafenib - Global
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
14 Mar 2018 |
Given that sorafenib has been shown to prolong the QT and QTc interval, which could lead to an increased risk of ventricular arrhythmia, two exclusion criteria were added to exclude subjects with a history of congenital long QT
syndrome or corrected QT interval >500 ms (calculated through the use of the Fridericia method) at screening and subjects with a history of uncorrectable electrolyte disorder
affecting serum levels of potassium, calcium, or magnesium. Under the same rationale, it was specified that caution is
recommended when administering sorafenib with certain anti-arrhythmic medicines or other medicinal products that lead to QT prolongation in sorafenib-treated participants. The stratification factors to be used for stratified analyses planned to be conducted for both co-primary efficacy endpoints, overall survival (OS) and overall response rate (ORR), were clarified. The following stratification factors were to be used for the stratified analyses that were planned to be conducted for both co-primary endpoints: geographic region (Asia excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline alpha-fetoprotein level (<400 vs. >/=400 ng/mL). Results from unstratified analyses may be provided as sensitivity analyses. Language to describe how the homogeneity of treatment effects across important patient subgroups will be descriptively assessed was added to the statistical details provided for the primary efficacy analyses of OS and ORR. The testing order of the key secondary endpoints was removed as the time to progression was no longer planned to be formally tested. The optional interim analysis was removed. |
||
15 Sep 2018 |
The co-primary endpoint of objective response rate (ORR) was changed to progression-free survival (PFS). ORR by investigator assessment was added as a secondary efficacy endpoint. The eligibility criteria were updated to refine the patient population, with the intent to ensure the safety of participants considering the toxicity profile of the study drugs. The window for assessing ECOG performance status, Child-Pugh Class A, and adequate hematologic and end-organ function lab tests was shortened from 14 days to 7 days prior to randomization to ensure fit participants were enrolled and to exclude subjects who could have progressively deteriorating liver function and overall health status. To ensure the safety of participants who would potentially receive bevacizumab (in combination with atezolizumab), the following eligibility criteria were modified/added: 1) Clarified the type of excluded, untreated or incompletely treated varices with bleeding or high risk for bleeding, esophageal and/or gastric varices in the relevant exclusion criteria; 2) The windows for previous stereotactic radiotherapy (within 7 days) and whole brain radiotherapy (within 14 days) were both extended to 28 days prior to initiation of study treatment; 3) A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment was added as an exclusion criterion; 4) Local therapy to liver within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure was added as an exclusion criterion. The requirement to hold bevacizumab or sorafenib treatment during palliative radiotherapy treatment and the need to obtain Medical Monitor approval prior to continuation of bevacizumab or sorafenib treatment upon completion of such therapy was added. For participants receiving sorafenib, prohibition of strong CYP3A inducers was removed. Additional atezolizumab anti-drug antibody (ADA) and PK samples were added. |
||
20 Feb 2019 |
The protocol was amended primarily to modify the statistical analysis plan to include a second interim analysis for overall survival (OS), which should be conducted when approximately 243 OS events (78% information fraction) have been observed. Guidelines for managing participants who experience atezolizumab-associated adverse events were revised to include guidelines for immune-related myositis. The secondary endpoint for patient reported outcomes of time to deterioration (TTD) was amended to align with the co-primary endpoints of progression-free survival and OS. The previous TTD endpoint was added as an exploratory endpoint. Modifications were made to the statistical analysis plan to add progression-free survival as the primary endpoint for the China subpopulation analysis to align with the global study analysis. Anaphylaxis Precautions appendix was modified to remove the
requirement for use of a tourniquet. The application of a tourniquet is no longer recommended due to the limited therapeutic benefit and risk of losing time for more important measures. Guidelines for managing participants who experience bevacizumab-associated adverse events were revised to update guidelines on proteinuria. |
||
15 Jan 2020 |
The protocol was modified primarily with an update to the risks and management guidelines for atezolizumab to align with the latest atezolizumab Investigator’s Brochure. |
||
01 Feb 2021 |
The descriptive and optional nature of subsequent overall survival (OS) analyses once statistical significance is reached at any of the pre-planned interim analyses of OS was clarified. Severe Cutaneous Adverse Reactions (SCARs) were added as a risk associated with atezolizumab. The Management Guidelines for Dermatologic Events was updated to include updated management guidelines for Grade 3 dermatologic events and new guidelines for Stevens-Johnson syndrome or toxic epidermal necrolysis of any grade were added. COVID-19 Considerations section was added to describe COVID-19-related risks. Exclusion criteria: Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia was updated to include any active infection that, the opinion of the investigator, could impact patient safety. COVID-19 risk language was included in the Safety Plan, to state that patients with an active infection were to be excluded from study participation.The Management Guidelines for Infusion-Related Reactions and Cytokine-Release Syndrome were updated to include COVID-19 risk language. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |